Form 4: Supernus Pharmaceuticals Executive Acquires Stock Options and Restricted Stock Units

Frank Mottola, SVP at Supernus Pharmaceuticals, reports acquisition of stock options and restricted stock units.

Summary

• Frank Mottola, a Senior Vice President at Supernus Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On February 19, 2025, Mottola acquired 20,000 employee stock options with an exercise price of $33.52, vesting in four equal annual installments starting February 19, 2026, and expiring on February 19, 2035.
• He also acquired 4,500 restricted stock units (RSUs), each representing one share of Supernus common stock, vesting in four equal annual installments beginning February 19, 2026.
• Mottola also owns 8,451 shares of common stock, including 251 shares acquired through the company's Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, aligning management interests with shareholders. There are no indications of negative events or concerns.

Positives

• The acquisition of stock options and RSUs aligns Mottola's interests with the company's long-term performance.
• The vesting schedules encourage continued service and contribution to Supernus Pharmaceuticals.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the pharmaceutical industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option and RSU grants are standard components of executive compensation packages in the pharmaceutical industry.
• Vesting schedules, typically over a four-year period, are also common to ensure long-term commitment.
• Comparing the size of the grant to similar companies like Jazz Pharmaceuticals or Neurocrine Biosciences would provide further context on the competitiveness of Supernus's compensation practices.

Stakeholder Impact

• The stock option and RSU grants could have a dilutive effect on existing shareholders, although this is a common practice.
• The grants incentivize the executive to improve company performance, which benefits shareholders.

Key Dates

Keywords

Supernus Pharmaceuticals, Form 4, Stock Options, Restricted Stock Units, Beneficial Ownership, Executive Compensation, Equity